There are currently 293 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT05313191
Recruiting
The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which uses high-energy waves to kill tumor cells. In some cases, the cancer either returns or a new tumor can present in a different part of the body. With the usual r... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: The New York Proton Center, New York, New York
Conditions: CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
Register for Updates
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT04812366
Recruiting
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of California Davis, Sacramento, California +8 locations
Conditions: Prostate Cancer
Register for Updates
ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
NCT05879913
Recruiting
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .
Gender:
MALE
Ages:
40 years and above
Trial Updated:
12/11/2024
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Prostate Cancer
Register for Updates
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT03769766
Recruiting
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Gender:
MALE
Ages:
Between 40 years and 89 years
Trial Updated:
12/09/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06235697
Recruiting
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri +8 locations
Conditions: Prostate Cancer
Register for Updates
A Study of a Pelvic Floor Muscle Exercise Program Before and After Radical Prostatectomy
NCT06671782
Recruiting
The researchers are doing this study to find out if a PFME program to reduce urinary incontinence after radical prostatectomy is feasible for people with prostate cancer. The researchers will track how many participants join the study, follow the program, and stay in the study. They will also evaluate how people feel about their experience and satisfaction with participating in this program through interviews. They will also measure participants' quality of life by filling out questionnaires, an... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Prostate Cancer
Register for Updates
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT05804318
Recruiting
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California +3 locations
Conditions: Prostate Cancer
Register for Updates
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
NCT04503265
Recruiting
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California +4 locations
Conditions: Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Register for Updates
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT06451497
Recruiting
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma
Register for Updates
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
NCT04808427
Recruiting
Background: The ability to treat early prostate cancer is still limited. Thermal ablation methods are being tested for focal prostate cancer therapy. Researchers want to improve on these methods. Objective: To understand if Transurethral UltraSound Ablation (TULSA) in combination with MRI guidance is useful to treat localized prostate cancer. Eligibility: English-speaking adults ages 18 and older with localized prostate cancer that can be seen on MRI and can be treated by thermal ablation.... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer
Register for Updates
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
NCT06705803
Recruiting
Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer of men in the world. In 2023 alone, it is estimated that 288,300 US men will be diagnosed with prostate cancer and 34,700 will die from the disease despite the approval of multiple systemic agents. Due to advances in screening and imaging technology, PCa is now detected much earlier in its disease course. Prostate gland ablation for prostate cancer might provide the option for a "middle" ground between active surveillance... Read More
Gender:
MALE
Ages:
22 years and above
Trial Updated:
11/22/2024
Locations: The University of Chicago, Hyde Park, Illinois +1 locations
Conditions: Prostate Cancer
Register for Updates
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629
Recruiting
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingd... Read More
Gender:
MALE
Ages:
21 years and above
Trial Updated:
11/21/2024
Locations: University of Alabama-Birmingham, Birmingham, Alabama +120 locations
Conditions: Prostate Cancer
Register for Updates